↓ Skip to main content

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Overview of attention for article published in New England Journal of Medicine, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Citations

dimensions_citation
1712 Dimensions

Readers on

mendeley
900 Mendeley
citeulike
3 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Published in
New England Journal of Medicine, November 2016
DOI 10.1056/nejmoa1609214
Pubmed ID
Authors

Douglas B Johnson, Justin M Balko, Margaret L Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R Alexander, Tyler L Bloomer, Jason R Becker, David A Slosky, Elizabeth J Phillips, Mark A Pilkinton, Laura Craig-Owens, Nina Kola, Gregory Plautz, Daniel S Reshef, Jonathan S Deutsch, Raquel P Deering, Benjamin A Olenchock, Andrew H Lichtman, Dan M Roden, Christine E Seidman, Igor J Koralnik, Jonathan G Seidman, Robert D Hoffman, Janis M Taube, Luis A Diaz, Robert A Anders, Jeffrey A Sosman, Javid J Moslehi

Abstract

Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab. In both patients, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with a robust presence of T-cell and macrophage infiltrates. Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumors and skeletal muscle. Pharmacovigilance studies show that myocarditis occurred in 0.27% of patients treated with a combination of ipilimumab and nivolumab, which suggests that our patients were having a rare, potentially fatal, T-cell-driven drug reaction. (Funded by Vanderbilt-Ingram Cancer Center Ambassadors and others.).

X Demographics

X Demographics

The data shown below were collected from the profiles of 365 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 900 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 <1%
Korea, Republic of 2 <1%
Sweden 1 <1%
Brazil 1 <1%
Canada 1 <1%
United Kingdom 1 <1%
Unknown 891 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 166 18%
Other 94 10%
Student > Ph. D. Student 78 9%
Student > Doctoral Student 65 7%
Student > Postgraduate 61 7%
Other 194 22%
Unknown 242 27%
Readers by discipline Count As %
Medicine and Dentistry 390 43%
Biochemistry, Genetics and Molecular Biology 56 6%
Agricultural and Biological Sciences 40 4%
Immunology and Microbiology 38 4%
Pharmacology, Toxicology and Pharmaceutical Science 21 2%
Other 70 8%
Unknown 285 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1326. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#9,887
of 25,559,053 outputs
Outputs from New England Journal of Medicine
#482
of 32,563 outputs
Outputs of similar age
#133
of 318,026 outputs
Outputs of similar age from New England Journal of Medicine
#12
of 286 outputs
Altmetric has tracked 25,559,053 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,563 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,026 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 286 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.